Stock PROC PROCAPS GROUP S.A.
Add to a list
To use this feature you must be a member
Log inSign up

Company Procaps Group S.A.

Equities

PROC

LU2376511205

Pharmaceuticals

Market Closed - Nasdaq
Other stock markets
 04:30:00 2024-04-25 pm EDT 		5-day change 1st Jan Change
2.727 USD -0.83% Intraday chart for Procaps Group S.A. +0.63% -33.00%
Mar. 04 Procaps Group S.A. Announces Formation of Strategic Committee to Explore Value Creation Alternatives CI
Mar. 04 Procaps Group Announces Formation of Strategic Committee to Explore Value Creation Alternatives CI

Business Summary

Procaps Group SA is a Luxembourg-based healthcare and pharmaceutical company. The Company develops, manufactures and sells prescription drugs and products that are differentiated by their combinations and pharmaceutical forms, as well as nutritional supplements which include omega 3 fish oils and high-potency clinical compounds. It operates its business through 5 units which are Diabetrics, Farma Procaps, Softi Gel, Vital Care, and Clinical Specialties. Diabetrics provides diabetes solutions. Farma procaps formulates, manufactures and markets branded prescription drugs in Latin America. Softi Gel provides contract drug development and manufacturing services to third party pharmaceutical companies. Vital Care develops, manufactures and markets consumer healthcare products. Clinical Specialties develops, manufactures and markets complex drugs.

Number of employees: 5,500

Managers

Managers TitleAgeSince
Jose Vieira CEO
 Chief Executive Officer - Dec. 31
Ruben Minski FOU
 Founder 72 75-12-31
Patricio Vargas Muñoz DFI
 Director of Finance/CFO 51 21-07-31
Luis Alberto Palacios Aragon CTO
 Chief Tech/Sci/R&D Officer 60 18-12-31
Manuel Camilo Camacho Pérez COO
 Chief Operating Officer 50 21-04-11
Melissa Angelini IRC
 Investor Relations Contact - 22-01-31
Maria Alejandra Molina LAW
 General Counsel - -
Mauricio Castañeda Caballero HRO
 Human Resources Officer 47 14-07-31
Marcela Carvajalino Pagano LAW
 General Counsel 57 12-12-31
Grethel Moreno Romero AUD
 Comptroller/Controller/Auditor 60 -

Members of the board

Members of the board TitleAgeSince
Juan Sartori
43 -
Alejandro Kostia N. Weinstein Crenovich BRD
 Director/Board Member 64 -
Kyle Bransfield BRD
 Director/Board Member 40 -
Alberto Eguiguren Correa BRD
 Director/Board Member 59 23-01-18
David Yanovich Wancier BRD
 Director/Board Member 53 -
Sandra Sanchez y Oldenhage BRD
 Director/Board Member - 23-10-22
Jose Minski BRD
 Director/Board Member 65 -
Ruben Minski FOU
 Founder 72 75-12-31
Luis Fernando Castro Vergara BRD
 Director/Board Member 57 -

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 112,824,183 19,147,994 ( 16.97 %) 0 16.97 %

Shareholders

NameEquities%Valuation
Ruben Minski
27.78 %
31,338,454 27.78 % 91 M $
Meyer Minski
15.92 %
17,960,146 15.92 % 52 M $
Jose Minski
15.92 %
17,960,146 15.92 % 52 M $
Alejandro Kostia N. Weinstein Crenovich
14.07 %
15,877,516 14.07 % 46 M $
International Finance Corp. (Investment Company)
7.527 %
8,492,427 7.527 % 25 M $
Kyle Bransfield
1.815 %
2,047,500 1.815 % 6 M $
Credicorp Capital Asset Management SA AGF
0.2247 %
253,548 0.2247 % 735 289 $
Exome Asset Management LLC
0.1125 %
126,901 0.1125 % 368 013 $
Lemanik Asset Management SA
0.0900 %
101,573 0.0900 % 294 562 $
G1 Execution Services LLC
0.0527 %
59,421 0.0527 % 172 321 $
NameEquities%Valuation
Highbridge Capital Management LLC
-
1,352,619 - 110 915 $
Walleye Capital LLC
-
1,223,694 - 100 343 $
LMR Partners LLP
-
1,059,854 - 86 908 $
Walleye Trading LLC
-
689,162 - 56 511 $
Davidson Kempner Capital Management LP
-
547,600 - 44 903 $
Cowen & Co. LLC
-
495,000 - 40 590 $
Tenor Capital Management Co. LP
-
400,000 - 32 800 $
Bluefin Capital Management LLC
-
316,091 - 25 919 $
Caption Management LLC
-
242,319 - 19 870 $
Union Square Park Capital Management LLC
-
200,000 - 16 400 $

Company contact information

Procaps Group SA

9 rue de Bitbourg

1273, Luxembourg

+

http://www.procapsgroup.com
address Procaps Group S.A.(PROC)

Sector

Healthcare
Pharmaceuticals & Medical Research
Pharmaceuticals
Pharmaceuticals
Other Pharmaceuticals

Ratings for Procaps Group S.A.

Trading Rating
Investor Rating
ESG Refinitiv
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
2
Last Close Price
2.727 USD
Average target price
4.75 USD
Spread / Average Target
+74.18%
Consensus

EPS Revisions

Estimates Revisions

Quarterly revenue - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

1st Jan change Capi.
PROCAPS GROUP S.A. Stock Procaps Group S.A.
-33.00% 308M
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+25.83% 653B
NOVO NORDISK A/S Stock Novo Nordisk A/S
+27.00% 556B
JOHNSON & JOHNSON Stock Johnson & Johnson
-6.76% 354B
MERCK & CO., INC. Stock Merck & Co., Inc.
+20.34% 331B
ABBVIE INC. Stock AbbVie Inc.
+3.00% 296B
ASTRAZENECA PLC Stock AstraZeneca PLC
+13.09% 233B
NOVARTIS AG Stock Novartis AG
+5.46% 201B
ROCHE HOLDING AG Stock Roche Holding AG
-9.61% 193B
AMGEN INC. Stock Amgen Inc.
-6.26% 144B
Other Pharmaceuticals
  1. Stock Market
  2. Equities
  3. PROC Stock
  4. Company Procaps Group S.A.